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Erythema gyratum repens (EGR) is a rare and characteristic, paraneoplastic rash associated with a
variety of malignancies, most notably lung, esophageal, and breast cancers. This case report details
the appearance, epidemiology, diagnosis, and treatment of EGR. Prompt identification of EGR is
essential, as the rash often precedes the diagnosis of malignancy by several months. Urgent patient
referral to evaluate for malignancy is crucial, as this may lead to decreased morbidity and mortality.
[West J Emerg Med. 2011;12(4):556–558.]
INTRODUCTION
Emergency physicians evaluate patients with rashes almost
daily. Many rashes are nonspeciﬁc and resolve with minimal
treatment, but some skin eruptions are pathognomonic for
serious systemic diseases. Erythema gyratum repens (EGR) is a
rare, and characteristic, rash strongly associated with
malignancy. In this case report, we describe the condition of a
61-year-old woman who presented with a generalized pruritic
eruption that was shown to be EGR. We discuss the appearance
of EGR, its epidemiology, and its diagnostic and treatment
implications.
CASE REPORT
A 61-year-old woman with a history of hypertension and
tobacco use presented to our emergency department (ED) with
a 6-month history of a generalized rash. She said the rash
started as a ‘‘bump’’ on her upper back and gradually spread to
involve her torso and extremities. The rash was associated with
extreme pruritus, erythema, and scaling (Figures 1 and 2).
Additional symptoms included a 22-lb weight loss, progressive
fatigue, anorexia, and intermittent vomiting. The patient
recently developed fevers, which prompted her primary care
physician to refer her to the ED. During the preceding 2
months, she had taken separate courses of corticosteroids and
antifungal medications without improvement in the rash. The
only medication she was taking at the time of ED presentation
was irbesartan. She had no known allergies, and her family
history was negative for connective tissue diseases and
malignancy.
Her vital signs at the time of ED presentation were a
temperature of 368C, pulse of 79 beats/minute, respiratory rate
of 16 breaths/minute, pulse oximetry reading of 100% on room
air, and blood pressure of 154/89 mmHg. She was not in any
distress but appeared uncomfortable because of the rash. Her
physical examination was notable for large, well-demarcated,
erythematous, plaquelike lesions with raised borders. The
lesions demonstrated desquamation and were arranged in
concentric circles that covered her thorax, back, abdomen, and
extremities. The lesions spared her palms and soles. No bullae,
Figure 1. Annular, erythematous rash lined by trailing edge of scale,
characteristic of erythema gyratum repens in this 61-year-old
female.
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examination was remarkable for axillary, inguinal, and anterior
and posterior cervical lymphadenopathy.
A complete blood chemistry revealed a white blood cell
count of 2.2 K/mcL with 4.5% eosinophils, a hematocrit of
34%, and a platelet count of 120 K/mcL. A comprehensive
metabolic panel was signiﬁcant only for a potassium
concentration of 2.7 mEq/L. A rapid plasma reagin test was
nonreactive and an anti-nuclear antibody test result was
negative. A chest ﬁlm showed hyperexpansion consistent with
chronic obstructive pulmonary disease but otherwise yielded
negative results. Computed tomography scans of the head,
neck, chest, abdomen, and pelvis demonstrated multiple
prominent lymph nodes in the anterior and posterior cervical
triangle, bilateral axillary lymphadenopathy, a 9-mm right
middle lobe lung nodule, a partially calciﬁed heterogeneous
pelvic mass, a tubular soft-tissue density suggestive of right
hemipelvic peritoneal mass, and areas of enhanced bone
lucencies suggestive of diffuse metastasis. These abnormalities
heightened concern for widespread malignancy such as diffuse
metastatic carcinoma with an uncertain primary site or, less
likely, melanoma or lymphoma.
A dermatology consultation was obtained and a 4-mm
punch biopsy specimen was taken from the patient’s left leg.
Histopathologic ﬁndings demonstrated thick parakeratotic
scale and scattered apoptotic cells, consistent with a diagnosis
of EGR.
From the ED, the patient was given prescriptions for
symptomatic management of her symptoms: hydroxyzine for
itching, ibuprofen and oxycodone for pain, and triamcinolone
0.1% cream for the rash. Subsequent outpatient evaluations and
procedures led to the diagnosis of adenocarcinoma of
gastrointestinal origin. Despite aggressive chemotherapy, the
patient died 9 months after her initial ED presentation.
DISCUSSION
Initially described by Gammel
1 in 1952 in a patient with
metastatic breast cancer, EGR is a paraneoplastic rash
associated with a variety of malignancies. The most common
are bronchial carcinoma, esophageal cancer, and breast
cancer.
2–4 In fact, EGR is considered one of the most distinctive
cutaneous manifestations of solid tumors.
2,4,5 Less commonly,
EGR is seen in patients with genitourinary, gastrointestinal, and
hematologic malignancies.
3,4,6 Rarely, EGR is seen in patients
with nonneoplastic conditions such as tuberculosis,
hypereosinophilic syndrome, bullous pemphigoid, pemphigus
vulgaris, systemic lupus erythematosus, and ulcerative
colitis.
4,6–10 Erythema gyratum repens most often occurs in
Caucasians, with a male to female ratio of 2:1. The average age
of onset is in the seventh decade of life.
2–4 When associated
with malignancy, EGR often precedes the diagnosis of cancer
by several months.
2–5
On examination, EGR has a characteristic appearance
consisting of wavy erythematous concentric bands that can be
ﬁgurate, gyrate, or annular. These bands are arranged in
parallel rings and lined by a ﬁne trailing edge of scale, a pattern
often described as ‘‘wood grained.’’
2–5,11,12 Erythema gyratum
repens can expand as fast as 1 cm a day. It typically involves
large areas of the body but tends to spare the face, hands, and
feet.
2–4 On occasion, bullae form within the areas of erythema.
2
The pruritus associated with EGR, an almost universal
symptom, can be extreme and debilitating.
2–5
Despite the characteristic skin appearance, EGR has
nonspeciﬁc histopathologic features. Biopsy specimens display
acanthosis, mild hyperkeratosis, focal parakeratosis, and
spongiosis conﬁned to the epidermis and superﬁcial dermis.
2–5
Mononuclear, lymphocytic, and histiocytic perivascular
inﬁltrate in the superﬁcial plexus can also be seen.
2,4,5
Basement membrane deposits of IgG, C3, or C4 have been
noted under direct immunoﬂuorescence in some cases.
4,5
Although the exact cause of EGR is unknown, various
immunologic mechanisms have been implicated in its
pathogenesis.
4,5 One theory is that the tumor may induce
antibodies that cross-react with the basement membrane of
skin.
2,5 Alternatively, some researchers propose that the tumor
may produce polypeptides that bind skin antigens and render
them immunogenic.
13 Still others postulate that deposition of
tumor antigen-antibody complexes onto the basement membrane
accounts for this reactive dermatitis. The observed
immunoﬂuorescence patterns of IgG, C3, and C4 at the basement
membrane corroborate a possible immunologic mechanism.
2
Although eosinophilia is observed in approximately 60%
of cases, the diagnosis of EGR is clinical. Given its distinctive
appearance, the differential diagnosis for EGR is usually
narrow and includes gyrate erythematous eruptions, such as
necrolytic migratory erythema (NME), erythema annulare
centrifugum, (EAC) and erythema migrans.
2–4 Necrolytic
migratory erythema is usually seen in association with
Figure 2. Erythema gyratum repens rash located on the upper back
of this 61-year-old female with metastatic adenocarcinoma.
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areas, and consists of enlarging erythematous painful annular
plaques that form blisters centrally then erode, forming necrotic
areas. Lesions of NME typically heal with hyperpigmentation,
a characteristic not seen in EGR.
3 Erythema annulare
centrifugum resembles EGR in that it has pruritic concentric
lesions with central clearing and a trailing edge of scale.
However, EAC usually involves smaller areas of the trunk and
extremities, and it migrates at a much slower rate than the
lesions of EGR.
2,4 Erythema migrans, the lesion of Lyme
disease, begins as a papule at the site of the tick bite and
expands peripherally, eventually developing central clearing.
Unlike EGR, erythema migrans has no scaling and is a more
localized skin reaction.
4
Various dermatologic and immunosuppressive therapies
have been used to treat EGR. Systemic steroids are frequently
ineffective. Topical steroids, vitamin A, and azathioprine have
also failed to relieve skin manifestations.
2,4 Improvement or
resolution of EGR, and its associated intense pruritus, depends
on recognition and treatment of the underlying malignancy.
2–
5,11 In patients with widely metastatic disease, the response of
EGR to chemotherapy is variable.
2,4 In such cases, patients may
not experience resolution of the rash until just before the time
of death, a time of signiﬁcant immunosuppression.
2,4,14
CONCLUSION
Many patients present to the ED for evaluation of rashes.
Although most rashes are benign and improvewith topical therapy
alone, several are indicative of more serious pathology. Erythema
gyratum repens is not considered a dermatologic emergency in the
sense that immediate therapy is required, but it remains a ‘‘can’t
miss’’ dermatologic diagnosis. Erythema gyratum repens is a
paraneoplastic rash that often precedes the diagnosis of
malignancy by several months. With prompt ED recognition,
patients can be referred for urgent diagnostic evaluation.
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